NattoPharma’s research shows that moisture and mineral salts are critical variables for Vitamin K2 degradation, driving the need for a protective technology.
The Answer: CryoCap, a NattoPharma Advance Delivery Platform technology developed specifically for dry delivery applications pairing MenaQ7 Vitamin K2 as MK-7 with interactive compounds, such as alkaline minerals or oxidative ingredients.
CryoCap offers advanced protective technology, providing delivery for the most aggressive interactive formulations. Featuring a proprietary encapsulation process, NattoPharma uses MenaQ7, the all-trans all-active menaquinone ingredient at 96-98% concentrated MK-7. The encapsulation process utilises a unique chilled process to limit heat and incorporate the active MK-7 into a matrix that requires very little carrier and is hydrophobic, completely protecting against moisture in final formulations.
Vitamin K2, when protected from ultraviolet light, is stable in single-ingredient formulations, such as oils and powders, and in many combinations under most conditions. But when a product calls for a more complex formulation, NattoPharma’s CryoCap technology protects K2 in a myriad of environments – against mild minerals like calcium citrate, more aggressive mineral mixes such as marine mineral complexes. Our team works closely with our partners to develop the right solution for their product goals.
NattoPharma, the leader in Vitamin K2 R&D, has conducted rigorous “stress-testing” on our CryoCap technology, confirming our superiority to our competitors’ offerings.
MenaQ7, the Expert Brand, advances the field by providing the clinically validated Vitamin K2 in a robust delivery system, ensuring your customer the proven benefits for bone and heart health.
Contact NattoPharma today to learn more about CryoCap and to incorporate your formulation with our technology to ensure the most robust delivery of MenaQ7 Vitamin K2 as MK-7.